FROG · Investment summary · as of 4 August 2026
Priced for an operating path the record does not support
Business type: Inflection · scaling but economically observable
The operating path required by today's price is not achievable on the evidence.
At $82.50, FROG requires a 48% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 25%.
The bull case on JFrog is an operating-leverage story, not a growth story - management guides FY2026 revenue to +18.5% while promising +18.1% non-GAAP operating margin off a -17.3% GAAP base.
The conditions that would settle the disagreement are dated to August 2026.
The value rests on an exit multiple of 12.6x, a terminal operating margin of 27% and a 8.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Permanent impairment of 45-55%, to roughly $41 per share, on the UNBILLED-RPO REPLACEMENT CHAIN BREAKING. 40.6% of total RPO - $233.4m of $574.9m - is contracted but unbilled, up from 35.0% a year ago and 19.3% two years ago.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The bull case on JFrog is an operating-leverage story, not a growth story - management guides FY2026 revenue to +18.5% while promising +18.1% non-GAAP operating margin off a -17.3% GAAP base. |
| What do we forecast? | Revenue growth of 25% demonstrated; a terminal operating margin of 27%; an exit multiple of 12.6x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -42.9 percentage points. |
| What is it worth? | Twelve-month target $79.47, -4% from the struck price. Scenario-weighted expected return net of costs -6.0%. |
| Why now? | The first dated test of the thesis falls on 6 August 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| Q2-2026 (Aug 2026) and Q3-2026 (Nov 2026) | Unbilled RPO exceeds 46% of total RPO in any quarter, or calculated… | Unbilled RPO no more than 46% of total RPO in any quarter, or calculated billings grow below revenue for two further… | Unbilled RPO exceeds 46% of total RPO in any quarter, or calculated billings grow below revenue for two further… |
| any quarter | Trailing-four-quarter net dollar retention falls back below 116% | Trailing-four-quarter net dollar retention falls back at or above 116% | Trailing-four-quarter net dollar retention falls back below 116% |
| Q3-2026 (Nov 2026) | Cloud revenue growth decelerates below 30% year-over-year (it was… | Cloud revenue growth decelerates at or above 30% year-over-year (it was +50.0% in Q1-2026 and has not been below 40%… | Cloud revenue growth decelerates below 30% year-over-year (it was +50.0% in Q1-2026 and has not been below 40% since… |
| each quarter; this leg carries 61% of the GAAP margin expansion | Stock-based compensation stops falling as a share of revenue, i.e.… | Stock-based compensation stops falling as a share of revenue, i.e. TTM SBC/revenue rises at or below 28.3% | Stock-based compensation stops falling as a share of revenue, i.e. TTM SBC/revenue rises above 28.3% |
Permanent impairment of 45-55%, to roughly $41 per share, on the UNBILLED-RPO REPLACEMENT CHAIN BREAKING. 40.6% of total RPO - $233.4m of $574.9m - is contracted but unbilled, up from 35.0% a year ago and 19.3% two years ago. The contracts are non-cancellable, so the fragility is not cancellation; it is CONTINUOUS REPLACEMENT.
Estimated probability 22%, against the 20% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
No position is held, so the rung is stated prospectively. On approach to the $79.47 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Permanent impairment of 45-55%, to roughly $41 per share, on the UNBILLED-RPO REPLACEMENT CHAIN BREAKING. 40.6% of total RPO - $233.4m of $574.9m - is contracted but unbilled, up from 35.0% a year ago and 19.3% two years ago. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -42.9 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: permanent impairment of 45-55%, to roughly $41 per share, on the UNBILLED-RPO REPLACEMENT CHAIN BREAKING. 40.6% of total RPO - $233.4m of $574.9m - is contracted but unbilled, up from 35.0% a year ago and 19.3% two years ago. The next evidence that should change the portfolio decision is the test dated 6 August 2026, or a daily close below $68.12, which forces an immediate review.